ALN-CIDEB

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Metabolic Dysfunction-Associated SteatohepatitisMetabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-Associated Steatotic Liver Disease

Phase 1

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

RecruitingNCT06836609

Regeneron PharmaceuticalsMetabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-Associated Steatotic Liver Disease

Start: 2025-04-28End: 2027-05-15Target: 132Updated: 2026-07-08

Phase 2

Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Not yet recruitingNCT07631637

Regeneron PharmaceuticalsMetabolic Dysfunction-Associated Steatohepatitis (MASH)

Start: 2026-07-15End: 2029-02-06Target: 150Updated: 2026-06-08